|
|
Vaccine Detail
|
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007579
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- HLA-DRB1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vaccine is made by conjugating tumor-derived Id protein with immunogenic foreign carrier protein keyhole limpet hemocyanin (KLH) using maleimide-sulfhydryl chemistry (Kafi et al., 2009).
- Description: A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immuno-stimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response. (NCI04) (NCIT_C38715).
This vaccine has been used in clinical trials involving Progressive Non-Hodgkin's Lymphoma. NCT00104819
|
| Host Response |
|
|
| References |
Kafi et al., 2009: Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Molecular immunology. 2009; 46(3); 448-456. [PubMed: 19046770].
NCIT_C38715: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38715]
|
|
